Beam 制药

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $78
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/5/21
• 评级变动
  Freedom Capital Markets Downgrades Beam Global(BEEM.US) to Hold Rating, Maintains Target Price $1.5
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• 评级变动
  BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• Maxim Group Maintains Beam Global(BEEM.US) With Buy Rating, Cuts Target Price to $3
  \u5e02\u573a\u8d44\u8baf · 2026/8/22
• JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 公司公告
  Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
  SEC · 2026/2/3
• 评级变动
  Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• 评级变动
  Freedom Capital Markets Initiates Beam Global(BEEM.US) With Buy Rating, Announces Target Price $1.5
  \u5e02\u573a\u8d44\u8baf · 2026/7/18
• 评级变动
  J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Shimizu has added a 1.5-hour fire-resistant specification to its Hi-Wood Beam product lineup.
  Shimizu · 2026/9/3
• A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 公司公告
  Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
  SEC · 2026/4/7
• 评级变动
  Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• 评级变动
  HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
  Benzinga · 2026/7/7
• 公司公告
  Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
  SEC · 2026/4/2
• 评级变动
  A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $43 to $78
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 公司公告
  4: Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
  SEC · 2026/7/2
• H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 公司公告
  Okabe: Regarding the release of the "Slab Dandol" side‑hanging hardware for main joists and the "Sokoukeitai" bottom support for beam formwork.
  JPX · 2026/10/5

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。